Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | PKM | P14618 | 2/20 | 0.77 |
| ▸ | DHODH | Q02127 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.63 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183709 | 1.00 | KMT2A (0.77) | KMT2AMEN1PKMDHODHPOLB | |
| SCHEMBL31053873 | 0.96 | MEN1 (0.83) | KMT2AMEN1PKMDHODHPOLB | |
| SCHEMBL414754 | 0.96 | MEN1 (0.83) | KMT2AMEN1PKMDHODHPOLB | |
| SCHEMBL8439303 | 0.94 | MEN1 (0.80) | KMT2AMEN1PKMDHODHPOLB | |
| SCHEMBL2028671 | 0.92 | DHODH (0.86) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL12700422 | 0.89 | DHODH (0.81) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL14856050 | 0.89 | DHODH (0.69) | KMT2AMEN1PKMDHODHMAPT | |
| SCHEMBL14855847 | 0.89 | MEN1 (0.70) | KMT2AMEN1PKMDHODHPOLB | |
| SCHEMBL14855907 | 0.88 | DHODH (0.73) | KMT2AMEN1PKMDHODHPOLB | |
| SCHEMBL4670044 | 0.87 | DHODH (0.78) | KMT2AMEN1PKMDHODHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | claimed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | claimed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | claimed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | claimed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20210024934-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2021-01-28 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024934-A1 | USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | FUBP1, FUBP3, SERBP1 | KMT2A 2358/4885MEN1 4075/4885PKM 4275/4885 |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | FUBP1, FUBP3, SERBP1 | KMT2A 2358/4885MEN1 4075/4885PKM 4275/4885 |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, EIF2AK2 | KMT2A 4008/4885MEN1 4366/4885PKM 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.